Healthcare in China
22 verified figures for China, covering 13 indicators from 2 primary sources. Every figure links to the report it came from.
China compared
| Measure | China | World | Highest country |
|---|---|---|---|
| Oncology novel active substance (NAS) launches (cumulative) | 84China · 2020–2024 | 132World · 2020–2024 | 85United States · 2020–2024 |
| Change in regional share of global clinical trial country uses | 57%China · 2019–2023 | — | 57%China · 2019–2023 |
| Domestic-only oncology NAS launches (cumulative) | 45China · 2020–2024 | — | 45China · 2020–2024 |
| Health and social services investment growth rate | -13%China · January 2026 | — | -13%China · January 2026 |
| Health care and medical services price index growth rate | 2.7%China · August 2026 | — | 2.7%China · August 2026 |
| Manufacture of medicines producer price index growth rate (monthly) | -0.2%China · August 2026 | — | -0.2%China · August 2026 |
The short version
Key takeaways
Affordability
- Traditional Chinese medicines price index (monthly) averaged 0% in August 2026 (NBS China). NBS China ↗ T1 Official
- Health care and medical services price index growth rate in China came in at 2.7% in August 2026 (NBS China). NBS China ↗ T1 Official
- Manufacture of medicines producer price index growth rate in China (monthly) came in at -0.2% in August 2026 (NBS China). NBS China ↗ T1 Official
- Medical services price index in China (monthly) averaged 0.1% in August 2026 (NBS China). NBS China ↗ T1 Official
Other
- Novel active substances launched exclusively in China stood at 30 in 2025 (IQVIA). IQVIA ↗
- Domestic-only oncology NAS launches in China (cumulative) stood at 45 in 2020–2024 (IQVIA). IQVIA ↗
- Medicine use index in China (2020=100) stood at 100 index in 2020 (IQVIA). IQVIA ↗
- Oncology novel active substance (NAS) launches in China (cumulative) stood at 84 in 2020–2024 (IQVIA). IQVIA ↗
- Change in regional share of global clinical trial country uses in China came in at 57% in 2019–2023 (IQVIA). IQVIA ↗
- Health and social services investment growth rate in China came in at -13% in January 2026 (NBS China). NBS China ↗ T1 Official
The complete table
Healthcare data for China
Every row links to its own page with the full source, verbatim quote and citation.
22 data points across 13 indicators. Each line shows the latest value; open a line for earlier periods and forecasts.
IndicatorPeriodValueSourceType
Change in regional share of global clinical trial country uses2019–202357%IQVIA2023actual→
Domestic-only oncology NAS launches (cumulative)2020–202445IQVIA2024actual→
Health and social services investment growth rateJanuary 2026-13%NBS ChinaT12026actual→
Health care and medical services price index growth rate +2 more August 20262.7%NBS ChinaT12026actual→
Manufacture of medicines producer price index growth rate (monthly) +1 more August 2026-0.2%NBS ChinaT12026actual→
Medical services price index (monthly) +1 more August 20260.1%NBS ChinaT12026actual→
Medicine use index (2020=100)2020100 indexIQVIA2020actual→
Novel active substances launched exclusively in China +1 more 202530IQVIA2025actual→
Oncology novel active substance (NAS) launches (cumulative) +1 more 2020–202484IQVIA2024actual→
Pharmaceutical manufacturing investment growth rateJanuary 2026-9.8%NBS ChinaT12026actual→
Traditional Chinese medicines price index (monthly) +1 more August 20260%NBS ChinaT12026actual→
Value added growth rate of pharmaceutical manufacturing +1 more July 20262.8%NBS ChinaT12026actual→
Western medicines price index (monthly) +1 more August 2026-0.1%NBS ChinaT12026actual→
Primary documents
Sources
| Document | Publisher | Authority tier | Published | Accessed | Locator | Data points |
|---|---|---|---|---|---|---|
| Investment in Fixed Assets from January to July 2026 Press release | NBS China | T1 Official | — | 15 Sep 2026 | Table: Investment in Fixed Assets (Excluding Rural Households) from January to July 2026 | 2 |
| Consumer Price Index in August 2026 Press release | NBS China | T1 Official | — | 16 Sep 2026 | I. Year-on-Year Changes in Price Indexes for Various Goods and Services; Consumer Price Indexes in August 2026 | 8 |
| National Economy Remained Steady with Innovation-Led and High-Quality Development in August Press release | NBS China | T1 Official | — | 15 Sep 2026 | 7. Consumer Price Rose Mildly and Producer Prices for Industrial Products Grew Faster Year on Year. | 1 |
| Industrial Producer Price Indexes in August 2026 Press release | NBS China | T1 Official | — | 15 Sep 2026 | Table: Industrial Producer Price Indexes in August 2026 — III. Producer Price Indexes for Major Industries (Growth Rate M/M column); Table: Industrial Producer Price Indexes in August 2026 — III. Producer Price Indexes for Major Industries (Jan-Aug Growth Rate Y/Y column) | 2 |
| Industrial Production Operation in July 2026 Press release | NBS China | T1 Official | — | 15 Sep 2026 | Value Added of the Main Industries | 2 |
| Rethinking Clinical Trial Country Prioritization Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Key findings | 1 |
| Global Oncology Trends 2025 Press release | IQVIA | T3 Research | — | 16 Sep 2026 | Other Findings | 3 |
| Global Medicine Use Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Key Findings | 1 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Key Findings | 1 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Key Findings | 1 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
All 22 collected records for China are published as verified.
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. Each figure's own page carries APA, MLA, Chicago and BibTeX citations naming its original publisher.
StatOrigin. (2026). Healthcare in China: statistics. Retrieved from https://statorigin.org/industries/healthcare/china